HCA Healthcare, Inc. (HCA) stock
HCANYSEServices-General Medical & Surgical Hospitals, NECFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/301% below fair value
$473.19−4.89 (-1.02%)
Close on Oct 30, 2026Market cap $102.45BP/E 15.7Yield 0.61%
Earnings
HCA Healthcare's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Jan 26, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$19.85B
+3.6% on a year earlier
diluted earnings per share, as adjusted, Q3 FY2026
$7.22
$6.96 a year earlier
Latest guidance
Issued
Oct 27, 2026 · 4 items
Quarterly results
Revenue and earnings per share from each of HCA Healthcare's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Jan 26, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 27, 2026before the open | $19.85B | +3.6% | $7.27 | $7.22 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 14, 2026before the open | $20.23B | +8.7% | $7.62 | $7.59 | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 24, 2026before the open | $19.11B | +4.3% | $7.15 | $7.15 | Release |
| Q4 FY2025ended Dec 31, 2025 | Jan 27, 2026before the open | $19.51B | +6.7% | $8.14 | $8.01 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 24, 2025before the open | $19.16B | +9.6% | $6.96 | $6.96 | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 25, 2025before the open | $18.61B | +6.4% | $6.83 | $6.84 | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 25, 2025before the open | $18.32B | +5.7% | $6.45 | $6.45 | Release |
| Q4 FY2024ended Dec 31, 2024 | Jan 24, 2025before the open | $18.29B | +5.7% | $5.63 | $6.22 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 25, 2024before the open | $17.49B | +7.9% | $4.88 | $4.90 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 23, 2024before the open | $17.49B | +10.3% | $5.53 | $5.50 | Release |
| Q1 FY2024ended Mar 31, 2024 | Apr 26, 2024before the open | $17.34B | +11.2% | $5.93 | $5.36 | Release |
| Q4 FY2023ended Dec 31, 2023 | Jan 30, 2024before the open | $17.30B | +11.7% | $5.93 | $5.90 | Release |
| Q3 FY2023ended Sep 30, 2023 | Oct 24, 2023before the open | $16.21B | +8.3% | $3.91 | $3.91 | Release |
| Q2 FY2023ended Jun 30, 2023 | Jul 27, 2023before the open | $15.86B | +7.0% | $4.29 | $4.29 | Release |
| Q1 FY2023ended Mar 31, 2023 | Apr 21, 2023before the open | $15.59B | +4.3% | $4.85 | $4.93 | Release |
| Q4 FY2022ended Dec 31, 2022 | Jan 27, 2023before the open | $15.50B | +2.9% | $7.28 | $4.64 | Release |
| Q3 FY2022ended Sep 30, 2022 | Oct 21, 2022before the open | $14.97B | -2.0% | $3.91 | $3.93 | Release |
| Q2 FY2022ended Jun 30, 2022 | Jul 22, 2022before the open | $14.82B | – | $3.90 | $4.21 | Release |
| Q1 FY2022ended Mar 31, 2022 | Apr 22, 2022before the open | $14.95B | – | $4.14 | $4.12 | Release |
| Q4 FY2021ended Dec 31, 2021 | Jan 27, 2022before the open | $15.06B | – | $5.75 | $4.42 | Release |
| Q3 FY2021ended Sep 30, 2021 | Oct 22, 2021before the open | $15.28B | – | $7.00 | $4.57 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 20, 2021before the open | – | – | – | – | Release |
| Q1 FY2021ended Mar 31, 2021 | Apr 22, 2021before the open | – | – | – | – | Release |
| Q4 FY2020ended Dec 31, 2020 | Feb 2, 2021before the open | – | – | – | – | Release |
| Q3 FY2020ended Sep 30, 2020 | Oct 8, 2020during market hours | – | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
HCA Healthcare's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| RevenuesGAAP | FY2026 | $77.00B – $79.50B | – | New | Oct 27, 2026 |
| Revenues | FY2026 | $77.00B – $79.50B | $76.50B – $80.00B | Narrowed | Jul 14, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $15.40B – $16.10B | – | New | Oct 27, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $15.40B – $16.10B | $15.55B – $16.45B | Lowered | Jul 14, 2026 |
| Diluted earnings per share: Net income attributable to HCA Healthcare, Inc.GAAP | FY2026 | $28.70 – $30.50 | – | New | Oct 27, 2026 |
| EPS (diluted)GAAP | FY2026 | $28.70 – $30.50 | $29.10 – $31.50 | Lowered | Jul 14, 2026 |
| capital expenditures | FY2026 | $5.00B – $5.50B | $5.00B – $5.50B | Reaffirmed | Jul 14, 2026 |
| Net income attributable to HCA Healthcare, Inc.GAAP | FY2026 | $6.30B – $6.70B | – | New | Oct 27, 2026 |
| Net Income Attributable to HCA Healthcare, Inc. | FY2026 | $6.30B – $6.70B | – | New | Jul 14, 2026 |
Guidance vs results
The last range HCA Healthcare gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | EPS (GAAP) | $27.00 – $28.00 | $28.38Σ4Q | Above range |
| FY2025 | Revenue | $75.00B – $76.50B | $75.60BΣ4Q | Within range |
Guidance history
Every forecast HCA Healthcare put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 27, 2026 | Adjusted EBITDA | FY2026 | $15.40B – $16.10B | New |
| Oct 27, 2026 | Diluted earnings per share: Net income attributable to HCA Healthcare, Inc. | FY2026 | $28.70 – $30.50 | New |
| Oct 27, 2026 | Net income attributable to HCA Healthcare, Inc. | FY2026 | $6.30B – $6.70B | New |
| Oct 27, 2026 | Revenues | FY2026 | $77.00B – $79.50B | New |
| Jul 14, 2026 | capital expenditures | FY2026 | $5.00B – $5.50B | Reaffirmed |
| Jul 14, 2026 | Adjusted EBITDA | FY2026 | $15.40B – $16.10B | Lowered |
| Jul 14, 2026 | EPS (diluted) | FY2026 | $28.70 – $30.50 | Lowered |
| Jul 14, 2026 | Net Income Attributable to HCA Healthcare, Inc. | FY2026 | $6.30B – $6.70B | New |
| Jul 14, 2026 | Revenues | FY2026 | $77.00B – $79.50B | Narrowed |
| Apr 24, 2026 | Adjusted EBITDA | FY2026 | $15.55B – $16.45B | New |
| Apr 24, 2026 | Diluted earnings per share: Net income attributable to HCA Healthcare, Inc. | FY2026 | $29.10 – $31.50 | Reaffirmed |
| Apr 24, 2026 | Revenues | FY2026 | $76.50B – $80.00B | Reaffirmed |
| Jan 27, 2026 | Capital expenditures | FY2026 | $5.00B – $5.50B | New |
| Jan 27, 2026 | EPS (diluted) | FY2026 | $29.10 – $31.50 | New |
| Jan 27, 2026 | Revenues | FY2026 | $76.50B – $80.00B | New |
| Oct 24, 2025 | Capital expenditures | FY2025 | $5.00B | Reaffirmed |
| Oct 24, 2025 | Adjusted EBITDA | FY2025 | $15.25B – $15.65B | New |
| Oct 24, 2025 | EPS (diluted) | FY2025 | $27.00 – $28.00 | New |
| Oct 24, 2025 | Revenues | FY2025 | $75.00B – $76.50B | New |
| Jul 25, 2025 | Capital expenditures | FY2025 | $5.00B | New |
| Apr 25, 2025 | Adjusted EBITDA | FY2025 | $14.30B – $15.10B | Reaffirmed |
| Apr 25, 2025 | Diluted earnings per share: Net income attributable to HCA Healthcare, Inc. | FY2025 | $24.05 – $25.85 | Reaffirmed |
| Apr 25, 2025 | Revenues | FY2025 | $72.80B – $75.80B | Reaffirmed |
| Jan 24, 2025 | Capital expenditures | FY2025 | $5.00B – $5.20B | New |
| Jan 24, 2025 | Adjusted EBITDA | FY2025 | $14.30B – $15.10B | New |
| Jan 24, 2025 | EPS (diluted) | FY2025 | $24.05 – $25.85 | New |
| Jan 24, 2025 | Net Income Attributable to HCA Healthcare, Inc. | FY2025 | $5.85B – $6.29B | New |
| Jan 24, 2025 | Revenues | FY2025 | $72.80B – $75.80B | New |
| Oct 25, 2024 | Capital expenditures | FY2024 | $5.00B | Lowered |
| Oct 25, 2024 | Adjusted EBITDA | FY2024 | $13.75B – $14.25B | Reaffirmed |
| Oct 25, 2024 | Diluted earnings per share: Net income attributable to HCA Healthcare, Inc. | FY2024 | $21.60 – $22.80 | Reaffirmed |
| Oct 25, 2024 | Revenues | FY2024 | $69.75B – $71.75B | Raised |
| Jul 23, 2024 | Capital expenditures | FY2024 | $5.10B – $5.30B | Reaffirmed |
| Jul 23, 2024 | Adjusted EBITDA | FY2024 | $13.75B – $14.25B | Raised |
| Jul 23, 2024 | EPS (diluted) | FY2024 | $21.60 – $22.80 | Raised |
| Jul 23, 2024 | Net Income Attributable to HCA Healthcare, Inc. | FY2024 | $5.68B – $5.98B | Raised |
| Jul 23, 2024 | Revenues | FY2024 | $69.75B – $71.75B | Raised |
| Apr 26, 2024 | Adjusted EBITDA | FY2024 | $12.85B – $13.55B | Reaffirmed |
| Apr 26, 2024 | Diluted earnings per share: Net income attributable to HCA Healthcare, Inc. | FY2024 | $19.70 – $21.20 | Reaffirmed |
| Apr 26, 2024 | Shares used in computing diluted earnings per share (millions) | FY2024 | 264 | New |
| Apr 26, 2024 | Net income attributable to HCA Healthcare, Inc. | FY2024 | $5.20B – $5.60B | New |
| Apr 26, 2024 | Depreciation and amortization | FY2024 | $3.20B – $3.27B | Lowered |
| Apr 26, 2024 | Interest expense | FY2024 | $1.99B – $2.04B | Lowered |
| Apr 26, 2024 | Provision for income taxes | FY2024 | $1.62B – $1.74B | Lowered |
| Apr 26, 2024 | Net income attributable to noncontrolling interests | FY2024 | $850.00M – $900.00M | Lowered |
| Apr 26, 2024 | Revenues | FY2024 | $67.75B – $70.25B | New |
| Jan 30, 2024 | Capital expenditures | FY2024 | $5.10B – $5.30B | New |
| Jan 30, 2024 | Adjusted EBITDA | FY2024 | $12.85B – $13.55B | New |
| Jan 30, 2024 | EPS (diluted) | FY2024 | $19.70 – $21.20 | New |
| Jan 30, 2024 | Net Income Attributable to HCA Healthcare, Inc. | FY2024 | $5.20B – $5.60B | New |
| Jan 30, 2024 | Revenues | FY2024 | $67.75B – $70.25B | New |
| Oct 24, 2023 | Adjusted EBITDA | FY2023 | $12.30B – $12.60B | Lowered |
| Oct 24, 2023 | EPS (diluted) | FY2023 | $17.80 – $18.50 | Narrowed |
| Oct 24, 2023 | Net Income Attributable to HCA Healthcare, Inc. | FY2023 | $4.94B – $5.13B | Narrowed |
| Oct 24, 2023 | Revenues | FY2023 | $63.50B – $64.50B | Narrowed |
| Jul 27, 2023 | Capital expenditures | FY2023 | $4.70B | Raised |
| Jul 27, 2023 | Adjusted EBITDA | FY2023 | $12.30B – $12.80B | Raised |
| Jul 27, 2023 | EPS (diluted) | FY2023 | $17.70 – $18.90 | Raised |
| Jul 27, 2023 | Net Income Attributable to HCA Healthcare, Inc. | FY2023 | $4.90B – $5.26B | Raised |
| Jul 27, 2023 | Revenues | FY2023 | $63.25B – $64.75B | Raised |
| Apr 21, 2023 | Capital expenditures | FY2023 | $4.60B | Raised |
| Apr 21, 2023 | Adjusted EBITDA | FY2023 | $12.10B – $12.70B | Raised |
| Apr 21, 2023 | EPS (diluted) | FY2023 | $17.25 – $18.55 | Raised |
| Apr 21, 2023 | Net Income Attributable to HCA Healthcare, Inc. | FY2023 | $4.75B – $5.16B | Raised |
| Apr 21, 2023 | Revenues | FY2023 | $62.50B – $64.50B | New |
| Jan 27, 2023 | Capital expenditures | FY2023 | $4.30B | New |
| Jan 27, 2023 | Adjusted EBITDA | FY2023 | $11.80B – $12.40B | New |
| Jan 27, 2023 | EPS (diluted) | FY2023 | $16.40 – $17.60 | New |
| Jan 27, 2023 | Net Income Attributable to HCA Healthcare, Inc. | FY2023 | $4.53B – $4.90B | New |
| Jan 27, 2023 | Revenues | FY2023 | $61.50B – $63.50B | New |
| Apr 22, 2022 | Adjusted EBITDA | FY2022 | $11.80B – $12.40B | Lowered |
| Apr 22, 2022 | EPS (diluted) | FY2022 | $16.40 – $17.60 | Lowered |
| Apr 22, 2022 | Net Income Attributable to HCA Healthcare, Inc. | FY2022 | $4.95B – $5.34B | Lowered |
| Apr 22, 2022 | Revenues | FY2022 | $59.50B – $61.50B | New |
| Jan 27, 2022 | Capital expenditures | FY2022 | $4.20B | New |
| Jan 27, 2022 | Adjusted EBITDA | FY2022 | $12.55B – $13.05B | New |
| Jan 27, 2022 | EPS (diluted) | FY2022 | $18.40 – $19.20 | New |
| Jan 27, 2022 | Net Income Attributable to HCA Healthcare, Inc. | FY2022 | $5.55B – $5.84B | New |
| Jan 27, 2022 | Revenues | FY2022 | $60.00B – $62.00B | New |
| Oct 22, 2021 | Capital Expenditures | FY2021 | $3.70B | New |
| Oct 22, 2021 | Adjusted EBITDA | FY2021 | $12.50B – $12.80B | New |
| Oct 22, 2021 | EPS (diluted) | FY2021 | $17.20 – $17.80 | New |
| Oct 22, 2021 | Revenues | FY2021 | $58.70B – $59.30B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases HCA Healthcare filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- Results
- Results
- News
- Results
- Results
- Results
- News
- Results
- Results
- Results
- Results